Atossa Therapeutics (ATOS) recently publicized their COVID-19 drug development program, COVID-19 HOPE. The company is using a novel combination of two FDA approved drugs, to create their AT-H201 product candidate. The company believes that AT-H201 could improve lung function and reduce the amount of time that patients are on ventilators. AT-H201's preclinical data showed impressive results that AT-H201 thwarts COVID-19's ability to infect VERO cells in a laboratory culture. What is more, AT-H201 outperformed Gilead's (GILD) Remdesivir and Hydroxychloroquine in the same test. In addition, the company announced a second COVID-19